TCTR20210225005已完成3 期
Efficacy and safety of gemigliptin as add-on therapy to insulin, with or without metformin, in patients with type 2 diabetes mellitus
G Chem Life Sciences Ltd.0 个研究点目标入组 290 人开始时间: 2021年2月25日最近更新:
适应症
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 发起方
- 入组人数
- 290
研究概览
简要总结
Gemigliptin added to insulin alone or to insulin in combination with metformin resulted in superior glycaemic control compared to that in the placebo group and was well tolerated for 24 weeks in patients with type 2 diabetes mellitus, without causing weight gain or increasing the incidence of hypoglycaemia.
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 19 Years 至 99 Years（—）
- 性别
- All
入选标准
- •Patients with type 2 diabetes mellitus of 19 years and above of age at the time of Visit 1 (Screening) and other details in https://clinicaltrials.gov/ct2/show/NCT02831361
排除标准
- •Patients with type 1 diabetes mellitus, gestational diabetes, or secondary diabetes and other details as in https://clinicaltrials.gov/ct2/show/NCT02831361
研究者
相似试验
已完成
3 期
Efficacy and Safety of Gosogliptin as Monotherapy and in Combination With Metformin vs. Vildagliptin as Monotherapy and in Combination With Metformin in Drug-naive Type 2 Diabetic Patients.Diabetes Mellitus, Type 2NCT03088670SatRx LLC299
已完成
不适用
Empagliflozin-based Quadruple Combination vs Insulin Glarine-based Combination Therapy in Patients With Type 2 DiabetesDiabetes Mellitus, Type 2NCT03473262Chungbuk National University Hospital200
已完成
3 期
Insulin Glargine Combination Therapies in Type II DiabeticsDiabetes Mellitus, Type 2NCT00783744Sanofi375
招募中
不适用
Efficacy of alogliptin/metformin combination tablets(INISYNC combination tablets) in type 2 diabetic patients.Type 2 diabetesJPRN-UMIN000034599Minami Osaka hospital120
已完成
3 期
A Study to Assess the Addition of Sitagliptin to Metformin Compared With the Addition of Dapagliflozin to Metformin in Participants With Type 2 Diabetes Mellitus (T2DM) and Mild Renal Impairment Who Have Inadequate Glycemic Control on Metformin With or Without a Sulfonylurea (MK-0431-838)Type 2 Diabetes MellitusNCT02532855Merck Sharp & Dohme LLC614